Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024 - Seite 2

The evaluation of HER2 status via tissue biopsy is the current standard of care for guiding breast cancer patient treatment plans. However, tissue biopsy is invasive and difficult to repeat throughout the patient care pathway. Moreover, discordance between a primary tumour sample and a metastatic site is common. Liquid biopsy evaluation of HER2 status is a minimally invasive technique, suitable for repeat monitoring and capturing changes in disease status during and after treatment. Specifically, CTCs, as a liquid biopsy analyte have shown considerable potential to provide key information on HER2 status in breast cancer patients. One third-party study of 575 breast cancer patients found that HER2 status had changed in 38% of patients from the original primary tissue biopsy to the metastatic tissue biopsy, at disease recurrence¹.

ANGLE Chief Scientific Officer, Karen Miller, commented:
"We are delighted to be presenting results from our HER2 assay development programme at the AACR's Annual Meeting as one of the key annual events in the cancer research calendar. We are excited to engage with the multidisciplinary community of attendees at this preeminent event to showcase this novel HER2 assay in partnership with BioView."

BioView Chief Scientific Officer, Chassidy Johnson commented:
"We are pleased to present both analytical and clinical data to support this novel HER2 assay being developed in collaboration with ANGLE. We believe this HER2 CTC assay has potential to greatly impact metastatic breast cancer patient care and look forward to this presentation at the 2024 AACR Annual Meeting."

About the AACR:
The AACR is the first and largest cancer research organisation dedicated to the prevention and cure of cancer. The AACR Annual Meeting is described as the focal point of the cancer research community, where cutting edge innovations in cancer science and medicine are presented from internationally renowned researchers and institutions. The annual conference is attended by scientists, clinicians, healthcare professionals, patient advocates and industry representatives, with last year's conference attracting over 21,000 attendees.

1. Miglietta F et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021 Oct 12;7(1):137

For further information:

ANGLE plc	[phone]
Andrew Newland, Chief Executive